At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 189 enrolled
Drug / intervention
Dotarem +1 moredrug
Likely dose
Dotarem 0.2 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy Evaluation of Dotarem®-Enhanced MRA Compared to Gadovist®-Enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Limb Arterial Diseases
In Brief
A Phase 4 clinical trial evaluating Dotarem and Gadovist for Peripheral Arterial Disease. Completed, enrolled 189 participants across 1 site.
Detailed Summary
This study is an efficacy evaluation of Dotarem®-enhanced magnetic resonance angiography (MRA) compared to Gadovist®-enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Arterial Disease
CountriesAustria
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedDec 2009
Primary CompletionJun 2011
Study CompletionJan 2012
TodayJul 2026
First PostedDec 4, 2009
Enrollment StartOct 1, 2009
Primary CompletionJun 1, 2011
Study CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 16.6 years ago
Interventions
Dotaremdrug
DOTAREM, 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus
Gadovistdrug
Gadovist, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus